Compare Gartner Inc (IT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Novartis AG — how do they compare? Gartner Inc trades at $195.3 (market cap $12.34B), while Novartis AG trades at $143.11 (market cap $268.57B). The key difference: Novartis AG is far larger — about 21.8× Gartner Inc's market cap, and Novartis AG pays a 3.31% dividend while Gartner Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and Novartis AG for 82 Days on average.
| IT | NVS | |
|---|---|---|
Market Cap | $12.34B | $268.57B |
Volume | 919,809 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $258.17 | $168.62 |
52-Week Low | $125.68 | $121.80 |
Typical Hold Time | 64 Days | 82 Days |
Enterprise Value | $14.08B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $185.77, up 0.46% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 69.63% gross margin and 12% net income margin, though 2025 net income declined to $729 million. Recent news highlights AI advisory demand and a shareholder investigation, while analyst consensus is mixed with a $174.63 price target below the current price.
Outlook remains supported by high ROE and consulting industry growth, but risks include the shareholder fiduciary probe and volatile cash flows. The stock faces resistance near $188, with valuation metrics like P/E of 17.57 appearing reasonable if earnings stabilize.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
